Guven, G. S. Et Al. 2006. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.12, no.3 , 364-368.

Guven, G. S., Kilicaslan, A., Oz, S. G., Haznedaroglu, I. C., Kirazli, S., ASLAN, D., ... Soezen, T.(2006). Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.12, no.3, 364-368.

Guven, Gulay Et Al. "Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity," CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.12, no.3, 364-368, 2006

Guven, Gulay S. Et Al. "Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity." CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.12, no.3, pp.364-368, 2006

Guven, G. S. Et Al. (2006) . "Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity." CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.12, no.3, pp.364-368.

@article{article, author={Gulay Sain Guven Et Al. }, title={Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity}, journal={CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS}, year=2006, pages={364-368} }